- Home
- SCWO vs ANL Comparison
SCWO vs ANL Comparison
Compare SCWO & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCWO
- ANL
- Stock Information
- Founded
- SCWO 2021
- ANL 2004
- Country
- SCWO United States
- ANL Cayman Islands
- Employees
- SCWO N/A
- ANL N/A
- Industry
- SCWO Environmental Services
- ANL
- Sector
- SCWO Utilities
- ANL
- Exchange
- SCWO Nasdaq
- ANL Nasdaq
- Market Cap
- SCWO 56.4M
- ANL 51.7M
- IPO Year
- SCWO N/A
- ANL 2023
- Fundamental
- Price
- SCWO $0.21
- ANL N/A
- Analyst Decision
- SCWO
- ANL Hold
- Analyst Count
- SCWO 0
- ANL 1
- Target Price
- SCWO N/A
- ANL N/A
- AVG Volume (30 Days)
- SCWO 1.3M
- ANL 8.0K
- Earning Date
- SCWO 08-13-2025
- ANL 08-08-2025
- Dividend Yield
- SCWO N/A
- ANL N/A
- EPS Growth
- SCWO N/A
- ANL N/A
- EPS
- SCWO N/A
- ANL N/A
- Revenue
- SCWO $673,267.00
- ANL N/A
- Revenue This Year
- SCWO $5,945.19
- ANL N/A
- Revenue Next Year
- SCWO $106.82
- ANL N/A
- P/E Ratio
- SCWO N/A
- ANL N/A
- Revenue Growth
- SCWO 161.19
- ANL N/A
- 52 Week Low
- SCWO $0.16
- ANL $1.10
- 52 Week High
- SCWO $1.99
- ANL $4.10
- Technical
- Relative Strength Index (RSI)
- SCWO 34.48
- ANL 43.16
- Support Level
- SCWO $0.16
- ANL $1.48
- Resistance Level
- SCWO $0.44
- ANL $1.57
- Average True Range (ATR)
- SCWO 0.06
- ANL 0.08
- MACD
- SCWO -0.03
- ANL 0.01
- Stochastic Oscillator
- SCWO 17.86
- ANL 29.41
About SCWO 374Water Inc.
374Water Inc offers a technology that transforms wet wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, and forever chemicals (e.g., PFAS) into recoverable resources by focusing on waste as a valuable resource for water, energy, and minerals. The company's business activities include manufacturing processes and waste recycling and treatment processes, which currently involve the use, treatment, storage, transfer, handling and/or disposal of hazardous materials, chemicals and wastes.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.